Gland Pharma: When it rains, it pours!
Gland Pharma stock declined 20 per cent on May 19, post results that shocked investors20-05-2023
20-05-2023
Gland Pharma's miserable Q4 weighs on the stock; challenges galore ahead
Production line upgrade led to a shutdown in Gland Pharma's Pashamylaram Penems facility, contributing to the weak revenue performance19-05-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Audited Financial Results for the Quarter and Financial Year ended March 31, 2023.19-05-2023
Gland Pharma Results Earnings Call for Q4FY23
Conference Call with Gland Pharma Ltd. Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.19-05-2023
Gland Pharma Ltd - 543245 - Related Party Transactions For The Half Year Ended 31St March 2023
Related Party Transactions for the half year ended 31st March 202318-05-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Earnings Call for the quarter and financial year ended March 31, 202318-05-2023
Gland Pharma Ltd - 543245 - Board Meeting Outcome for Revised Outcome
Revised outcome-The unsigned covering letter was filed inadvertently earlier.18-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Gland Pharma Ltd.
Gland Pharma announced Q4FY23 & FY23 results: Revenue from operations for FY23, at Rs 36,246 million declined by 18% as compared to the previous year Rs 44,007 million. Revenue from operations during Q4FY23 has declined at Rs 7,850 million by 29% as compared to the corresponding quarter of the previous year Rs 11,030 million. Sale to US market is comprising of products sold to both US customers and Indian customers for US markets. For Q4FY23 direct sale to US customers Rs 4,233 million and to Indian customers for US markets was Rs 578 million, totalling Rs 4,808 million. During the quarter the Company has Launched 10 product SKUs. Rest of the World markets, accounted for 22% of Q4FY23 revenue for the quarter. EBITDA of Rs 10,248 million in FY23, as compared to Rs 15,102 million for the previous financial year, a decrease of 32%. The total R&D; expense for Q4FY23 was Rs 678 million which is 8.6% of revenue. During the year financial year, the Company has incurred Rs 2,014 million in R&D; which is 5.6% of revenue. During Q4FY23, the Company has filed 9 ANDAs, and received 7 ANDA approvals. As on March 31, 2023, we along with our partners has 334 ANDA filings in the United States, of which 263 were approved and 71 pending approvals. Commenting on the results, Mr. Srinivas Sadu, MD & CEO of Gland Pharma said “We have formally closed the acquisition of Cenexi and welcome it to be a part of the Gland-Fosun family. This is our first overseas acquisition and our move into the next phase of growth and expansion. We made progress on our path to building a Bio-CDMO and signed our first contract for Plasma Protein at our Shamirpet facility. Our full year FY23 revenue stood at Rs 36,246 Mn, and our full year FY23 PAT stood at Rs 7,810 Mn in the midst of challenging business environment. As an important milestone we received our first China approval and have also initiated launch of our first product. Our progress on the complex portfolio is in-line with plan and this year we filed a total of 3 complex products during the year. Our priority for the next year shall be seamless integration of Cenexi along with a focus on driving sustainable business growth”. Result PDF18-05-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on Q4FY23 Financial Results18-05-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Q4FY23 Financial Results.18-05-2023